GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forward Pharma A/S (OTCPK:FWPAY) » Definitions » Debt-to-Asset

Forward Pharma A/S (Forward Pharma A/S) Debt-to-Asset : 0.05 (As of Jun. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Forward Pharma A/S Debt-to-Asset?

Forward Pharma A/S's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $2.95 Mil. Forward Pharma A/S's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $0.00 Mil. Forward Pharma A/S's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2022 was $65.64 Mil. Forward Pharma A/S's debt to asset for the quarter that ended in Jun. 2022 was 0.04.


Forward Pharma A/S Debt-to-Asset Historical Data

The historical data trend for Forward Pharma A/S's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forward Pharma A/S Debt-to-Asset Chart

Forward Pharma A/S Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Forward Pharma A/S Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.05

Competitive Comparison of Forward Pharma A/S's Debt-to-Asset

For the Biotechnology subindustry, Forward Pharma A/S's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Forward Pharma A/S's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forward Pharma A/S's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Forward Pharma A/S's Debt-to-Asset falls into.



Forward Pharma A/S Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Forward Pharma A/S's Debt-to-Asset for the fiscal year that ended in Dec. 2021 is calculated as

Forward Pharma A/S's Debt-to-Asset for the quarter that ended in Jun. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Forward Pharma A/S  (OTCPK:FWPAY) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Forward Pharma A/S Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Forward Pharma A/S's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Forward Pharma A/S (Forward Pharma A/S) Business Description

Traded in Other Exchanges
N/A
Address
Ostergade 24A, 1st Floor, Copenhagen, DNK, 1100
Forward Pharma A/S is a biopharmaceutical company that engages in the research and production of medicinal treatments for multiple sclerosis and psoriasis.